Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 18:11:1134.
doi: 10.3389/fimmu.2020.01134. eCollection 2020.

Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling

Grzegorz Kardas  1 , Piotr Kuna  1 , Michał Panek  1
Affiliations
Review

Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling

Grzegorz Kardas et al. Front Immunol. .

Abstract

Asthma is a chronic and heterogenic respiratory tract disorder with a high global prevalence. The underlying chronic inflammatory process and airway remodeling (AR) contribute to the symptomatology of the disease. The most severely ill asthma patients may now be treated using a variety of monoclonal antibodies aiming key inflammatory cytokines involved in asthma pathogenesis. Although clinical data shows much beneficial effects of biological therapies in terms of reduction of exacerbation rates, improvement of lung functions, asthma control and patients' quality of life, little is known on the effects of these monoclonal antibodies on AR-a key clinical trait of long-term asthma management. In this review, the authors summarize the data on the proven effects of monoclonal antibodies in asthma on AR. To date, in terms of reversing AR, the mostly studied was omalizumab. However, some studies also addressed this clinical issue in context of other severe asthma biological therapies (mepolizumab, benralizumab, tralokinumab). Still, data on effects of particular biological therapies on AR in severe asthma are incomplete and require further studies. According to the American Thoracic Society research recommendations, future research shall focus on AR in asthma and improve drugs targeting AR, including the available and future monoclonal antibodies.

Keywords: airway remodeling; airway remodeling in asthma; asthma; benralizumab; biological therapy; mepolizumab/reslizumab; omalizumab.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. GINA Global Strategy for Asthma Management and Prevention Updated 2020. (2020). Available online at: www.ginasthma.org (accessed April 7, 2020).
    1. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. (2012) 18:716–25. 10.1038/nm.2678 - DOI - PubMed
    1. Liebhart J, Dobek R, Małolepszy J, Wojtyniak B, Pisiewicz K, Płusa T, et al. . The prevalence of allergic diseases in Poland-the results of the PMSEAD study in relation to gender differences. Adv Clin Exp Med. (2014) 23:757–62. 10.17219/acem/37238 - DOI - PubMed
    1. Samolinski B, Raciborski F, Lipiec A, Tomaszewska A, Krzych-Fałta E, Samel-Kowalik P, et al. Epidemiologia Chorób Alergicznych w Polsce (ECAP) Epidemiology of allergic diseases in Poland. Otolaryngol Pol. (2014) 1:10–8. 10.1016/j.alergo.2014.03.008 - DOI
    1. Schatz M, Rosenwasser L. The allergic asthma phenotype. J Allergy Clin Immunol Pract. (2014) 2:645–8. 10.1016/j.jaip.2014.09.004 - DOI - PubMed

MeSH terms

Substances